Quarterly ResultMay 5, 2026, 06:02 AM
Integra LifeSciences Q1 Revenue $391.9M; Adj EPS $0.54; Raises 2026 Adj EPS
AI Summary
Integra LifeSciences reported Q1 2026 revenues of $391.9 million, a 2.4% reported increase and 1.3% organic growth year-over-year. GAAP diluted EPS was $(0.06), an improvement from $(0.33) in the prior year, while adjusted diluted EPS rose to $0.54 from $0.41. The company reaffirmed its full-year 2026 revenue guidance of $1.662 billion to $1.702 billion and updated its adjusted EPS guidance from $2.30-$2.40 to $2.40-$2.50. Additionally, Stuart Essig was appointed President and CEO, and Michael McBreen was promoted to Chief Commercial Officer, as noted in a separate release.
Key Highlights
- Stuart Essig appointed President and CEO; Michael McBreen promoted to Chief Commercial Officer.
- Q1 2026 revenues of $391.9 million, up 2.4% reported and 1.3% organic YoY.
- Q1 2026 adjusted diluted EPS of $0.54, up from $0.41 in prior year.
- 2026 full-year revenue guidance reaffirmed: $1.662 billion to $1.702 billion.
- 2026 adjusted EPS guidance raised to $2.40-$2.50 from $2.30-$2.40.
- Specialty Surgery segment revenue: $283.1 million, +0.9% reported, (0.6)% organic.
- Tissue Reconstruction segment revenue: $108.8 million, +6.7% reported, +6.4% organic.
- Generated $9.8 million cash flow from operations in Q1 2026.